Overview

Efficacy and Safety Study of Moxidectin in Adults With Scabies

Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies.
Phase:
Phase 2
Details
Lead Sponsor:
Medicines Development for Global Health
Treatments:
Moxidectin